When is contralateral mastectomy warranted in unilateral breast cancer?

Expert Review of Anticancer Therapy

Volumn 11, Issue 8, 2011, Pages 1209-1214

  Barry, Mitchel ^a   Sacchini, Virgilio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

contralateral mastectomy; prophylactic mastectomy; risk reduction surgery; survival; unilateral breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ANXIETY; BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CONTRALATERAL PROPHYLACTIC MASTECTOMY; DISTANT METASTASIS; FAMILY HISTORY; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAMMOGRAPHY; MASTECTOMY; MOTIVATION; OVARIECTOMY; OVERALL SURVIVAL; PATIENT EDUCATION; PRIMARY TUMOR; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; PATIENT SELECTION; RISK FACTORS;

EID: 80052313399     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.100     Document Type: Review

References (42)

1. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J. Clin. Oncol. 25(33), 5203-5209 (2007).
2. Tuttle TM, Jarosek S, Habermann EB et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J. Clin. Oncol. 27(9), 1362-1367 (2009).
3. Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: A report from the National Cancer Data Base, 1998-2007. Ann. Surg. Oncol. 17(10), 2554-2562 (2010).
4. Schairer C, Brown LM, Mai PL. Inflammatory breast cancer: High risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Res. Treat. 129(1), 117-124 (2011).
5. Adami HO, Malker B, Meirik O et al. Age as a prognostic factor in breast cancer. Cancer 56(4), 898-902 (1985).
6. Nichols HB, de Gonzalez AB, Lacey JV Jr, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J. Clin. Oncol. 29(12), 1564-1569 (2011).
7. Herrinton LJ, Barlow WE, Yu O et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project. J. Clin. Oncol. 23(19), 4275-4286 (2005).
8. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J. Natl Cancer Inst. 102(6), 401-409 (2010).
9. Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann. Oncol. 20(9), 1505-1510 (2009).
10. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst. Rev. 11, CD002748 (2010).
11. Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am. J. Surg. 180(6), 439-445 (2000).
12. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62(3), 676-689 (1998).
13. Verhoog LC, Brekelmans CT, Seynaeve C et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351(9099), 316-321 (1998).
14. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283(5), 617-624 (2000).
15. van Sprundel TC, Schmidt MK, Rookus MA et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br. J. Cancer. 93(3), 287-292 (2005).
16. Metcalfe KA, Lubinski J, Ghadirian P et al.; Hereditary Breast Cancer Clinical Study Group. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The Hereditary Breast Cancer Clinical Study Group. J. Clin. Oncol. 26(7), 1093-1097 (2008).
17. Curry P, Fentiman IS. Management of women with a family history of breast cancer. Int. J. Clin. Pract. 53(3), 192-196 (1999).
18. Trau H, Schewach-Millet M, Fisher BK, Tsur H. Peutz-Jeghers syndrome and bilateral breast carcinoma. Cancer 50(4), 788-792 (1982).
19. Yi M, Hunt KK, Arun BK et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev. Res. 3(8), 1026-1034 (2010).
20. Gogas J, Markopoulos C, Skandalakis P, Gogas H. Bilateral breast cancer. Am. Surg. 59(11), 733-735 (1993).
21. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340(2), 77-84 (1999).
22. Vo TN, Meric-Bernstam F, Yi M et al. Outcomes of breast-conservation therapyfor invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am. J. Surg. 192(4), 552-555 (2006).
23. King TA, Gurevich I, Sakr R, Patil S, Stempel M, Morrow M. Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann. Surg. 254(1), 2-7 (2011).
24. De Bruin ML, Sparidans J, van't Veer MB et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes. J. Clin. Oncol. 27(26), 4239-4246 (2009).
25. Boyd NF, Byng JW, Jong RA et al. Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study. J. Natl Cancer Inst. 87(9), 670-675 (1995).
26. Habel LA, Capra AM, Achacoso NS et al. Mammographic density and risk of second breast cancer after ductal carcinoma in situ. Cancer Epidemiol. Biomarkers Prev. 19(10), 2488-2495 (2010).
27. Geiger AM, West CN, Nekhlyudov L et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J. Clin. Oncol. 24(9), 1350-1356 (2006).
28. Radovan C. Breast reconstruction after mastectomy using the temporary expander. Plast. Reconstr. Surg. 69(2), 195-208 (1982).
29. Schneider WJ, Hill HL Jr, Brown RG. Latissimus dorsi myocutaneous flap for breast reconstruction. Br. J. Plast. Surg. 30(4), 277-281 (1977).
30. Elliott LF, Hartrampf CR Jr. Tailoring of the new breast using the transverse abdominal island flap. Plast. Reconstr. Surg. 72(6), 887-893 (1983).
31. Frost MH, Slezak JM, Tran NV et al. Satisfaction after contralateral prophylactic mastectomy: The significance of mastectomy type, reconstructive complications, and body appearance. J. Clin. Oncol. 23(31), 7849-7856 (2005).
32. Montgomery LL, Tran KN, Heelan MC et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann. Surg. Oncol. 6(6), 546-552 (1999).
33. Jensen JA, Orringer JS, Giuliano AE. Nipple-Sparing mastectomy in 99 patients with a mean follow-up of 5 years. Ann. Surg. Oncol. 18(6), 1665-1670 (2010).
34. Hatcher MB, Fallowfield L, A'Hern R. The psychosocial impact of bilateral prophylactic mastectomy: Prospective study using questionnaires and semistructured interviews. Br. Med. J. 322(7278), 76 (2001).
35. Bresser PJ, Seynaeve C, Van Gool AR et al. The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. Eur. J. Cancer. 43(1), 95-103 (2007).
36. Brandberg Y, Sandelin K, Erikson S et al. Psychological reactions, quality of life,and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: A prospective 1-year follow-up study. J. Clin. Oncol. 26(24), 3943-3949 (2008).
37. Nyström L, Rutqvist LE, Wall S et al. Breast cancer screening with mammography: Overview of Swedish randomised trials. Lancet 341(8851), 973-978 (1993).
38. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J. Clin. Oncol. 22(6), 1055-1062 (2004).
39. Gelber RD, Cole BF, Goldhirsch A et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival. Lancet 347(9008), 1066-1071 (1996).
40. Goldflam K, Hunt KK, Gershenwald JE et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9), 1977-1986 (2004).
41. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J. Natl Cancer Inst. 101(15), 1058-1065 (2009).
42. Narod SA. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res. Treat. 128(2), 581-583 (2011).